141 related articles for article (PubMed ID: 37828033)
21. Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I study.
Yang J; Dong L; Yang S; Han X; Han Y; Jiang S; Yao J; Zhang Z; Zhang S; Liu P; Qin Y; Wu H; Feng H; Yao S; Sun Y; Song H; Shi Y
Eur J Cancer; 2020 May; 130():182-192. PubMed ID: 32224416
[TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC.
Gao S; Li N; Gao S; Xue Q; Ying J; Wang S; Tao X; Zhao J; Mao Y; Wang B; Shao K; Lei W; Wang D; Lv F; Zhao L; Zhang F; Zhao Z; Su K; Tan F; Gao Y; Sun N; Wu D; Yu Y; Ling Y; Wang Z; Duan C; Tang W; Zhang L; He S; Wu N; Wang J; He J
J Thorac Oncol; 2020 May; 15(5):816-826. PubMed ID: 32036071
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study.
Jiang H; Yu X; Li N; Kong M; Ma Z; Zhou D; Wang W; Wang H; Wang H; He K; Li Z; Lu Y; Zhang J; Zhao K; Zhang Y; Xu N; Li Z; Liu Y; Wang Y; Wang Y; Teng L
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35296556
[TBL] [Abstract][Full Text] [Related]
24. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
[TBL] [Abstract][Full Text] [Related]
25. Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02).
Wang FH; Wei XL; Feng J; Li Q; Xu N; Hu XC; Liao W; Jiang Y; Lin XY; Zhang QY; Yuan XL; Huang HX; Chen Y; Dai GH; Shi JH; Shen L; Yang SJ; Shu YQ; Liu YP; Wang W; Wu H; Feng H; Yao S; Xu RH
J Clin Oncol; 2021 Mar; 39(7):704-712. PubMed ID: 33492986
[TBL] [Abstract][Full Text] [Related]
26. Combination Therapy With Anti-PD-1 or PD-1 Antibody Alone in Asian Pediatric Patients With Relapsed or Refractory Cancer.
Que Y; Wang J; Zhu J; Li N; Huang J; Lu S; Sun F; Zhang L; Zhen Z; Zhang L; Cai R; Guo H; Sun X; Zhang Y
Front Immunol; 2021; 12():647733. PubMed ID: 34295326
[TBL] [Abstract][Full Text] [Related]
27. Assessment of TMB, PD-L1, and lymphocyte to monocyte ratio as predictive potential in a phase Ib study of sintilimab in patients with advanced solid tumors.
Jiang H; Li N; Wang H; Chen Z; Zheng Y; Qian J; Mao C; Xu X; Xiao C; Zhang X; Zhou H; Wang S; Chen W; Yin X; Sun J; Peng B; Teng L; Xu N
Am J Cancer Res; 2021; 11(9):4259-4276. PubMed ID: 34659886
[TBL] [Abstract][Full Text] [Related]
28. Real-World Efficacy and Safety of Sintilimab-Based Regimens against Advanced Esophageal Cancer: A Single-Center Retrospective Observational Study.
Wang C; Jin L; Cheng X; Ren R; Zheng A; Hao A; Wang N; Zhang J; Zhou F; Zhang Y
Biomed Res Int; 2022; 2022():7331687. PubMed ID: 36033564
[TBL] [Abstract][Full Text] [Related]
29. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
[TBL] [Abstract][Full Text] [Related]
30. Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1+ Non-Small Cell Lung Cancer Patients.
Zhou X; Zhou L; Yao Z; Huang M; Gong Y; Zou B; Zhu J; Liu Y; Peng F; Zhang Y; Yu M; Li Y; Na F; Wu Y; Kang K; Xiu W; Zhang X; Zhou L; Xu Y; Wang J; Wang Y; Yang X; Wu Y; Li R; Zhang Y; Yang Z; Zhou Z; Bai J; Yi X; Tong R; Yin L; Chen C; Niedermann G; Lu Y; Xue J
Clin Cancer Res; 2023 Oct; 29(20):4098-4108. PubMed ID: 37581611
[TBL] [Abstract][Full Text] [Related]
31. Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.
Jabbour SK; Berman AT; Decker RH; Lin Y; Feigenberg SJ; Gettinger SN; Aggarwal C; Langer CJ; Simone CB; Bradley JD; Aisner J; Malhotra J
JAMA Oncol; 2020 Jun; 6(6):848-855. PubMed ID: 32077891
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11).
Yang Y; Wang Z; Fang J; Yu Q; Han B; Cang S; Chen G; Mei X; Yang Z; Ma R; Bi M; Ren X; Zhou J; Li B; Song Y; Feng J; Li J; He Z; Zhou R; Li W; Lu Y; Wang Y; Wang L; Yang N; Zhang Y; Yu Z; Zhao Y; Xie C; Cheng Y; Zhou H; Wang S; Zhu D; Zhang W; Zhang L
J Thorac Oncol; 2020 Oct; 15(10):1636-1646. PubMed ID: 32781263
[TBL] [Abstract][Full Text] [Related]
33. Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trial.
Gong J; Cao J; Zhang Q; Xu N; Zhao Y; Xing B; Miao Z; Wu Y; Pan H; Gao Q; Li X; Liu B; Li W; Pei Z; Xia H; Qi Q; Dai H; Shi Q; Yang J; Li J; Shen L
Cancer Immunol Immunother; 2022 Aug; 71(8):1897-1908. PubMed ID: 34984540
[TBL] [Abstract][Full Text] [Related]
34. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials.
Fang W; Yang Y; Ma Y; Hong S; Lin L; He X; Xiong J; Li P; Zhao H; Huang Y; Zhang Y; Chen L; Zhou N; Zhao Y; Hou X; Yang Q; Zhang L
Lancet Oncol; 2018 Oct; 19(10):1338-1350. PubMed ID: 30213452
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.
Arrieta O; Barrón F; Ramírez-Tirado LA; Zatarain-Barrón ZL; Cardona AF; Díaz-García D; Yamamoto Ramos M; Mota-Vega B; Carmona A; Peralta Álvarez MP; Bautista Y; Aldaco F; Gerson R; Rolfo C; Rosell R
JAMA Oncol; 2020 Jun; 6(6):856-864. PubMed ID: 32271354
[TBL] [Abstract][Full Text] [Related]
36. Sintilimab in Patients with Previously Treated Metastatic Neuroendocrine Neoplasms.
Jia R; Li Y; Xu N; Jiang HP; Zhao CH; Liu RR; Shi Y; Zhang YY; Wang SY; Zhou H; Xu JM
Oncologist; 2022 Aug; 27(8):e625-e632. PubMed ID: 35647908
[TBL] [Abstract][Full Text] [Related]
37. Copy number loss in granzyme genes confers resistance to immune checkpoint inhibitor in nasopharyngeal carcinoma.
Ma Y; Chen X; Wang A; Zhao H; Lin Q; Bao H; Zhang Y; Hong S; Tang W; Huang Y; Yang Y; Wu X; Shao Y; Fang W; Zhang L
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737344
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of sintilimab-based regimens against advanced gastric and gastroesophageal junction adenocarcinoma.
Wang Y; Zhao J; Yu H; Wang J; Zhang N; Cao B
J Cancer Res Ther; 2021 Nov; 17(5):1234-1240. PubMed ID: 34850772
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of sintilimab in combination with chemotherapy in previously untreated advanced or metastatic nonsquamous or squamous NSCLC: two cohorts of an open-label, phase 1b study.
Jiang H; Zheng Y; Qian J; Mao C; Xu X; Li N; Xiao C; Wang H; Teng L; Zhou H; Wang S; Zhu D; Sun T; Yu Y; Guo W; Xu N
Cancer Immunol Immunother; 2021 Mar; 70(3):857-868. PubMed ID: 33070260
[TBL] [Abstract][Full Text] [Related]
40. Indirect comparison of sintilimab and other PD-L1 inhibitors for first-line treatment of non-squamous non-small-cell lung cancer.
Zhang L; Qian Y; Li J; Cui C; Chen L; Qu S; Lu S
Future Oncol; 2022 May; 18(15):1896-1905. PubMed ID: 35311347
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
